© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
LivaNova PLC (LIVN) stock declined over -0.47%, trading at $81.05 on NASDAQ, down from the previous close of $81.43. The stock opened at $81.90, fluctuating between $80.34 and $82.07 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 30, 2026 | 81.90 | 82.07 | 80.02 | 81.05 | 645.77K |
| Jul 29, 2026 | 81.99 | 82.70 | 80.47 | 81.43 | 501.96K |
| Jul 28, 2026 | 81.31 | 82.64 | 81.25 | 82.09 | 536.79K |
| Jul 27, 2026 | 78.85 | 80.64 | 78.31 | 80.58 | 486.53K |
| Jul 24, 2026 | 79.61 | 79.74 | 77.86 | 78.19 | 412.29K |
| Jul 23, 2026 | 76.63 | 78.69 | 75.30 | 78.61 | 707.17K |
| Jul 22, 2026 | 79.77 | 80.27 | 78.07 | 78.27 | 434.6K |
| Jul 21, 2026 | 79.15 | 79.97 | 78.83 | 79.85 | 444.44K |
| Jul 20, 2026 | 80.78 | 80.92 | 79.19 | 79.21 | 602.02K |
| Jul 17, 2026 | 80.55 | 82.05 | 79.96 | 80.70 | 445.74K |
| Jul 16, 2026 | 80.15 | 82.65 | 79.78 | 81.79 | 630.9K |
| Jul 15, 2026 | 78.69 | 80.75 | 78.07 | 79.41 | 723.37K |
| Jul 14, 2026 | 83.02 | 83.50 | 78.46 | 79.12 | 828.63K |
| Jul 13, 2026 | 83.44 | 83.80 | 82.45 | 82.98 | 464.96K |
| Jul 10, 2026 | 82.52 | 82.83 | 81.50 | 82.56 | 452.29K |
| Jul 09, 2026 | 82.54 | 83.94 | 81.72 | 82.52 | 612.06K |
| Jul 08, 2026 | 83.58 | 83.94 | 81.81 | 82.51 | 724.84K |
| Jul 07, 2026 | 84.74 | 84.77 | 82.48 | 83.58 | 439.56K |
| Jul 06, 2026 | 83.93 | 85.27 | 83.13 | 84.03 | 548.81K |
| Jul 02, 2026 | 83.07 | 83.75 | 82.00 | 83.62 | 517.43K |
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
| Employees | 3300 |
| Beta | 0.86 |
| Sales or Revenue | $1.15B |
| 5Y Sales Change% | -0.062% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |